重复转移灶定向放疗在寡复发前列腺癌中的结局与风险分层:大型跨国PSMA PET引导队列
该跨国PORTAL队列纳入177例PSMA PET检测的寡复发激素敏感性前列腺癌患者,均接受≥2轮转移灶定向放疗(MDRT)。从第二程MDRT起算,2年ADT无进展生存率为50.2%,多因素模型显示两程MDRT间隔较长和单发新病灶与更好的ADT-FS独立相关。
要点
- 重复MDRT后约半数患者2年内无需启动ADT。
- 两程MDRT间隔较长者ADT-FS更优(HR 0.96/月)。
- 第二程时≥2个新病灶者ADT-FS更差(HR 1.88)。
核心结论
- 在PSMA PET检测的寡复发前列腺癌重复MDRT队列中观察到较好的ADT-FS,约半数患者第二程MDRT后2年仍未启动ADT。
研究设计与样本
- 跨国PORTAL consortium的多中心队列研究,纳入177例PSMA PET检测的寡复发激素敏感性前列腺癌且接受≥2轮MDRT的患者。
主要发现
- 中位随访26.1个月,86例启动ADT,59例出现多转移,38例接受下一线系统治疗,17例死亡。
- 2年ADT-FS为50.2%(95%CI 41.4-58.3),2年无多转移生存为64.4%(95%CI 55.4-72.0)。
- 2年无下一线系统治疗生存为83.5%(95%CI 76.0-88.9),2年总生存为94.2%(95%CI 88.2-97.2)。
- 多因素Cox模型中,两程MDRT间隔较长(每延长1个月HR 0.96,95%CI 0.94-0.99;p=0.003)与ADT-FS独立相关。
- 治疗单发 vs ≥2个新病灶与ADT-FS独立相关(≥2个病灶HR 1.88,95%CI 1.22-2.90;p=0.006)。
关键数值与推荐
- 模型区分度中等(乐观校正C-index 0.68),校准良好。
临床怎么用
- 两程MDRT间隔和新增病灶数目可用于辅助筛选适合重复MDRT的患者。
- 无对照组,观察到的结局可能同时反映治疗效应与适合重复MDRT患者的有利疾病生物学。
局限性
- 缺少对照组,无法区分治疗效应与有利疾病生物学。
- 模型区分度中等(乐观校正C-index 0.68)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Repeated metastasis-directed radiotherapy (MDRT) is increasingly used in patients with metachronous oligometastatic prostate cancer. However, the efficacy and optimal patient selection criteria remain insufficiently defined. MATERIAL AND METHODS: Within the multinational PORTAL consortium, we evaluated outcomes of repeated MDRT in patients with prostate-specific membrane antigen positron emission tomography (PSMA-PET)-detected oligorecurrent hormone-sensitive prostate cancer undergoing ≥ 2 MDRT cycles. The primary endpoint was androgen deprivation therapy-free survival (ADT-FS), secondary endpoints included polymetastatic-free survival, next-line systemic therapy-free survival, and overall survival, all calculated from start of second MDRT. A multivariable Cox regression model was developed to predict ADT-FS, and its performance was evaluated by bootstrapped internal validation using discrimination (C-index) and calibration. RESULTS: A total of 177 patients were included. Median follow-up after second MDRT was 26.1 months. During follow-up, 86 patients initiated ADT, 59 developed polymetastatic disease, 38 received next-line systemic therapy, and 17 deaths occurred. Two-year ADT-FS was 50.2 % (95 % CI 41.4-58.3). Two-year polymetastatic-free, next-line systemic therapy-free, and overall survival were 64.4 % (95 % CI 55.4-72.0), 83.5 % (95 % CI 76.0-88.9), and 94.2 % (95 % CI 88.2-97.2), respectively. In the multivariable Cox regression model, a longer interval between first and second MDRT (HR 0.96 per month, 95 % CI 0.94-0.99; p = 0.003) and treatment of a single versus ≥ 2 new lesions (HR for ≥ 2 lesions 1.88, 95 % CI 1.22-2.90; p = 0.006) were independently associated with ADT-FS. Model discrimination was moderate (optimism-corrected C-index 0.68) with good calibration. CONCLUSIONS: In this multicentre cohort of patients with PSMA PET-detected metachronous oligorecurrent prostate cancer undergoing repeated MDRT, favourable ADT-FS outcomes were observed, with approximately half of patients remaining ADT-free two years after second MDRT. Given the absence of a comparator group, these outcomes may reflect both the effects of treatment and favourable disease biology of patients who remained eligible for repeated MDRT. The interval between MDRT cycles, and the number of metastases, independently predicted ADT-FS and may support patient selection.
引用
- van der Walle R, van Bergen TD, Miszczyk M, et al. Repeated metastasis-directed radiotherapy in patients with oligorecurrent prostate cancer: outcomes and risk stratification from a large multinational PSMA PET-guided cohort. Radiother Oncol. 2026. PMID: 42874780. doi:10.1016/j.radonc.2026.111821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。